Suzhou Highfine Biotech (301393) Stock Overview
Manufactures and sells chemicals for pharmaceutical research and development, and API production companies in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
301393 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Suzhou Highfine Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥51.89 |
| 52 Week High | CN¥63.80 |
| 52 Week Low | CN¥35.81 |
| Beta | 0.92 |
| 1 Month Change | -3.01% |
| 3 Month Change | -2.97% |
| 1 Year Change | 12.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -49.67% |
Recent News & Updates
Recent updates
Subdued Growth No Barrier To Suzhou Highfine Biotech Co., Ltd.'s (SZSE:301393) Price
Dec 24
With A 26% Price Drop For Suzhou Highfine Biotech Co., Ltd. (SZSE:301393) You'll Still Get What You Pay For
Apr 16Why Suzhou Highfine Biotech's (SZSE:301393) Shaky Earnings Are Just The Beginning Of Its Problems
Apr 15Shareholder Returns
| 301393 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.4% | 0.7% | 1.8% |
| 1Y | 12.0% | 17.6% | 24.1% |
Return vs Industry: 301393 underperformed the CN Pharmaceuticals industry which returned 17.6% over the past year.
Return vs Market: 301393 underperformed the CN Market which returned 24.1% over the past year.
Price Volatility
| 301393 volatility | |
|---|---|
| 301393 Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 301393 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 301393's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 428 | Yong Zhu | www.highfine.com |
Suzhou Highfine Biotech Co., Ltd. manufactures and sells chemicals for pharmaceutical research and development, and API production companies in China. The company’s products include characteristic amide bonds, building blocks, protein reagents, protein crosslinkers, peptide reagents, protective amino acids, ionic liquids, PROTAC reagents, unnatural amino acids, pharmaceutical reagents of liposomes and lipid nanoparticles, nucleotide reagents, etc. Its products are used in fields of peptide, nucleotide, and pharmaceutical synthesis. The company also exports its products.
Suzhou Highfine Biotech Co., Ltd. Fundamentals Summary
| 301393 fundamental statistics | |
|---|---|
| Market cap | CN¥5.55b |
| Earnings (TTM) | CN¥144.13m |
| Revenue (TTM) | CN¥497.12m |
Is 301393 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301393 income statement (TTM) | |
|---|---|
| Revenue | CN¥497.12m |
| Cost of Revenue | CN¥296.24m |
| Gross Profit | CN¥200.88m |
| Other Expenses | CN¥56.75m |
| Earnings | CN¥144.13m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 29, 2025
| Earnings per share (EPS) | 1.35 |
| Gross Margin | 40.41% |
| Net Profit Margin | 28.99% |
| Debt/Equity Ratio | 0% |
How did 301393 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 10:56 |
| End of Day Share Price | 2025/09/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Suzhou Highfine Biotech Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Kai Wang | Citic Securities Co., Ltd. |